Literature DB >> 27912983

Hypertrophic obstructive cardiomyopathy.

Josef Veselka1, Nandan S Anavekar2, Philippe Charron3.   

Abstract

Hypertrophic obstructive cardiomyopathy is an inherited myocardial disease defined by cardiac hypertrophy (wall thickness ≥15 mm) that is not explained by abnormal loading conditions, and left ventricular obstruction greater than or equal to 30 mm Hg. Typical symptoms include dyspnoea, chest pain, palpitations, and syncope. The diagnosis is usually suspected on clinical examination and confirmed by imaging. Some patients are at increased risk of sudden cardiac death, heart failure, and atrial fibrillation. Patients with an increased risk of sudden cardiac death undergo cardioverter-defibrillator implantation; in patients with severe symptoms related to ventricular obstruction, septal reduction therapy (myectomy or alcohol septal ablation) is recommended. Life-long anticoagulation is indicated after the first episode of atrial fibrillation.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27912983     DOI: 10.1016/S0140-6736(16)31321-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  49 in total

1.  Three-Dimensional Heart Printing for Planning of Septal Reduction Therapy in Patients with Hypertrophic Obstructive Cardiomyopathy.

Authors:  Josef Veselka; Theodor Adla; Radka Adlova; Thomas Bartel
Journal:  Int J Angiol       Date:  2018-04-19

Review 2.  Risk stratification in hypertrophic cardiomyopathy.

Authors:  S Marrakchi; I Kammoun; E Bennour; L Laroussi; S Kachboura
Journal:  Herz       Date:  2018-04-25       Impact factor: 1.443

Review 3.  Hypertrophic cardiomyopathy: an updated review on diagnosis, prognosis, and treatment.

Authors:  George Makavos; Chris Κairis; Maria-Eirini Tselegkidi; Theodoros Karamitsos; Angelos G Rigopoulos; Michel Noutsias; Ignatios Ikonomidis
Journal:  Heart Fail Rev       Date:  2019-07       Impact factor: 4.214

Review 4.  Genetics of dilated cardiomyopathy: practical implications for heart failure management.

Authors:  Andrew N Rosenbaum; Katherine E Agre; Naveen L Pereira
Journal:  Nat Rev Cardiol       Date:  2019-10-11       Impact factor: 32.419

5.  G3BP2 is involved in isoproterenol-induced cardiac hypertrophy through activating the NF-κB signaling pathway.

Authors:  Hui-Qi Hong; Jing Lu; Xiu-Li Fang; Yu-Hong Zhang; Yi Cai; Jing Yuan; Pei-Qing Liu; Jian-Tao Ye
Journal:  Acta Pharmacol Sin       Date:  2017-08-17       Impact factor: 6.150

6.  Ventricular tachycardia and heart failure in a patient of mid-ventricular obstructive hypertrophic cardiomyopathy with apical aneurysm: A case report.

Authors:  Xin Zhang; Xingbin Liu
Journal:  Exp Ther Med       Date:  2019-07-19       Impact factor: 2.447

Review 7.  Targeting Mitochondrial Calcium Handling and Reactive Oxygen Species in Heart Failure.

Authors:  Alexander Dietl; Christoph Maack
Journal:  Curr Heart Fail Rep       Date:  2017-08

8.  Hypertrophic Cardiomyopathy Is Associated with Altered Left Ventricular 3D Blood Flow Dynamics.

Authors:  Judith T Pruijssen; Bradley D Allen; Alex J Barker; Robert O Bonow; Lubna Choudhury; James C Carr; Michael Markl; Pim van Ooij
Journal:  Radiol Cardiothorac Imaging       Date:  2020-02-27

Review 9.  Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy.

Authors:  Daniel J Philipson; Eugene C DePasquale; Eric H Yang; Arnold S Baas
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

10.  Head-Up Tilt Test in Risk Stratification of Patients with Hypertrophic Cardiomyopathy.

Authors:  Hana Sediva; T Hnat; J Bonaventura; J Slesarenko; J Veselka
Journal:  Int J Angiol       Date:  2019-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.